首页> 外文会议>Conference on medical imaging >A B-Spline Image Registration Based CAD Scheme to Evaluate Drug Treatment Response of Ovarian Cancer Patients
【24h】

A B-Spline Image Registration Based CAD Scheme to Evaluate Drug Treatment Response of Ovarian Cancer Patients

机译:基于B样条图像配准的CAD方案评估卵巢癌患者的药物治疗反应

获取原文

摘要

Ovarian cancer is the second most common cancer amongst gynecologic malignancies, and has the highest death rate. Since the majority of ovarian cancer patients (>75%) are diagnosed in the advanced stage with tumor metastasis, chemotherapy is often required after surgery to remove the primary ovarian tumors. In order to quickly assess patient response to the chemotherapy in the clinical trials, two sets of CT examinations are taken pre- and post-therapy (e.g., after 6 weeks). Treatment efficacy is then evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST) guideline, whereby tumor size is measured by the longest diameter on one CT image slice and only a subset of selected tumors are tracked. However, this criterion cannot fully represent the volumetric changes of the tumors and might miss potentially problematic unmarked tumors. Thus, we developed a new CAD approach to measure and analyze volumetric tumor growth/shrinkage using a cubic B-spline deformable image registration method. In this initial study, on 14 sets of pre- and post-treatment CT scans, we registered the two consecutive scans using cubic B-spline registration in a multiresolution (from coarse to fine) framework. We used Mattes mutual information metric as the similarity criterion and the L-BFGS-B optimizer. The results show that our method can quantify volumetric changes in the tumors more accurately than RECIST, and also detect (highlight) potentially problematic regions that were not originally targeted by radiologists. Despite the encouraging results of this preliminary study, further validation of scheme performance is required using large and diverse datasets in future.
机译:卵巢癌是妇科恶性肿瘤中第二常见的癌症,死亡率最高。由于大多数卵巢癌患者(> 75%)被诊断为患有肿瘤转移的晚期,因此手术后通常需要进行化学疗法以去除原发性卵巢肿瘤。为了在临床试验中快速评估患者对化疗的反应,在治疗前和治疗后(例如,在6周后)进行了两组CT检查。然后,根据实体瘤反应评估标准(RECIST)指南评估治疗效果,从而通过一个CT图像切片上的最长直径来测量肿瘤大小,并且仅跟踪所选肿瘤的一个子集。但是,该标准不能完全代表肿瘤的体积变化,并且可能会遗漏可能引起问题的未标记肿瘤。因此,我们开发了一种新的CAD方法,使用三次B样条可变形图像配准方法来测量和分析体积肿瘤的生长/收缩。在这项初步研究中,在14组治疗前后的CT扫描中,我们使用立方B样条配准在多分辨率(从粗到精细)框架中配准了两次连续扫描。我们使用Mattes互信息度量作为相似度标准,并使用L-BFGS-B优化器。结果表明,与RECIST相比,我们的方法可以更准确地量化肿瘤的体积变化,还可以检测(突出显示)放射科医生最初未瞄准的潜在问题区域。尽管这项初步研究取得了令人鼓舞的结果,但未来仍需要使用大量不同的数据集来进一步验证方案的性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号